MRNA | NASDAQ
Next Earnings: Aug 14, 2026
Company Overview:
7.7 Year MRNA Performance Metrics:
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]MRNA Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for MRNA
Based on past 7.7-year performance, here are MRNA growth metrics:
Share price CAGR of +17.32%
Dividend CAGR of +0%
Using MRNA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| MRNA (DRIP) | MRNA - No DRIP | |
|---|---|---|
| Current Price | $63.65 | $63.65 |
| Start Shares | 157.11 | 157.11 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 157.11 | 157.11 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $314.54 | $63.65 |
| Total Dividends | $0 | $0 |
| Final Value | $49,417 | $10,000 |
NOTE: Above numbers are our estimate based on MRNA's Dividend and Price CAGR over past 7.7 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
Moderna, Inc. (MRNA) had its IPO on 2018-12-07, and is trader on NASDAQ stock exchange.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA website: https://www.modernatx.com
